Hormone Therapy Linked to Lower Heart Risk
Women who started hormone therapy near menopause saw a lower risk of cardiovascular disease events.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Do you trust that starting hormone therapy during menopause reduces your long-term heart disease risk?
A long-term study has found that initiating menopausal hormone therapy is associated with a reduced risk of fatal and nonfatal cardiovascular disease events. The research suggests that the timing of therapy relative to the onset of menopause significantly influences these outcomes.
Why it matters
This finding highlights how the timing of hormone interventions may serve as a crucial factor in long-term heart health for women entering menopause. Understanding these windows of benefit can help patients and clinicians better navigate cardiovascular risk management strategies.
Using cohort data collected from 1997 to 2017, researchers analyzed 2,737 women to evaluate hormone therapy. The study found an adjusted hazard ratio of 0.78 for cardiovascular events among those who initiated therapy, though results varied significantly based on how long after menopause treatment began.
The players
University of Pittsburgh School of Public Health
An academic institution involved in the research regarding the impact of hormone therapy on cardiovascular outcomes.
The details
Researchers utilized data from the Study of Women's Health Across the Nation to compare cardiovascular outcomes between women who initiated hormone therapy and those who did not. The analysis showed a hazard ratio of 0.73 for those starting within 10 years of menopause, while starting more than 10 years after was associated with a ratio of 1.53. Notably, Black women in the cohort who initiated therapy had an adjusted hazard ratio of 0.51.
Timeline
1997 to 2017: Cohort data was collected for the study.
September 8, 2026: The study was published.
Health Landscape
This study advances the 'timing hypothesis' in endocrinology, which suggests that the physiological benefits of hormone therapy depend on the proximity of initiation to menopause. It adds significant nuance to the broader historical debate surrounding the cardiovascular safety of menopausal hormone treatments.
These findings suggest that the timing of hormone therapy initiation may be a critical factor to review with your healthcare provider. If you are approaching or navigating menopause, discuss your cardiovascular risk profile and whether a hormone-based intervention aligns with your personal health goals.
The takeaway
The window of time between menopause onset and the start of hormone therapy appears to be a key variable in cardiovascular risk. Patients should monitor their heart health markers closely and consult their physician to evaluate how these findings apply to their specific medical history.
Further reading
For more information on preventing heart issues, visit the Heart Disease section.
Live Poll
Do you trust that starting hormone therapy during menopause reduces your long-term heart disease risk?
